肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2023年CSCO《乳腺癌诊疗指南》更新要点解读

2023-06-20 中国人民解放军总医院第五医学中心肿瘤医学部 中国肿瘤外科杂志 发表于上海

乳腺癌

该文总结了2023版CSCO乳腺癌诊疗指南早期乳腺癌部分的更新要点，并进行了详细解读。

中文标题：

2023年CSCO《乳腺癌诊疗指南》更新要点解读

发布机构：

中国人民解放军总医院第五医学中心肿瘤医学部

发布日期：

2023-06-20

简要介绍：

2023版CSCO乳腺癌诊疗指南基于循证医学证据和领域专家共识，考虑到国情及诊疗产品的可及性，在乳腺癌分类分层治疗的指导原则下，对乳腺癌的全程规范化治疗指南进行了更新和修订。该文总结了2023版CSCO乳腺癌诊疗指南早期乳腺癌部分的更新要点，并进行了详细解读。
 

相关资料下载：
2023年CSCO《乳腺癌诊疗指南》更新要点解读.pdf
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2024-03-07 中和制药东哥 来自湖南省

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-11-13 ms8000000455478267 来自江苏省

    如何获得积分下载？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-11-12 ms6000001473620636 来自广西

    对临床工作有很大指导意义！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-09-22 ms8000001769177689

    非常有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-08-15 1467790cm53暂无昵称 来自浙江省

    有用

    0

相关指南

美国国家综合癌症网络临床实践指南：乳腺癌更新解读(2023V4)

哈尔滨医科大学附属肿瘤医院 · 2023-06-20

乳腺癌新辅助治疗中外指南对比解读

厦门大学附属翔安医院 · 2023-06-20

第三届关于乳房恶性潜在性不明的病变(B3病变)的国际共识会议

欧洲乳腺癌专科学会(EUSOMA,European Society of Breast Cancer Specialists) · 2023-06-17

2023 ASCO/CAP指南：人表皮生长因子受体2检测在乳腺癌中的应用（更新版）

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2023-06-07

2023 ESMO共识声明：HER2低表达乳腺癌的定义，诊断和管理

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2023-06-01

乳腺癌患者芳香化酶抑制剂诱导的骨关节症状预防和管理的证据总结

复旦大学护理学院 · 2023-04-10

拓展阅读

乳腺癌步入“慢病”时代，徐兵河院士详解乳腺癌防治要点

【医悦汇】特邀中国工程院徐兵河院士做客“科普ONCO”栏目，分享乳腺癌防治前沿观点。

【专家述评】｜早期乳腺癌局部治疗与全身治疗的进展与展望

本文就早期乳腺癌局部和系统性治疗的现状、研究进展及展望予以综述，旨在为广大临床工作者提供参考。

【综述】｜NRP-1靶向分子探针助力乳腺癌诊断的最新进展及展望

本文对NRP-1靶向分子探针在乳腺癌诊断中的优缺点进行系统比较，并阐述各类探针在乳腺癌诊疗领域的适用范围及最新研究进展，以期为乳腺癌靶向分子探针的研发及临床应用提供参考。

直击乳腺癌|热点资讯引领，课程、指南等全面赋能医疗人

此次，本文收集的乳腺癌热点资讯聚焦当下最热门话题，为你打开新视野。精心筹备的课程由业内资深人士倾囊相授，深入浅出地讲解乳腺癌相关知识。新近发布的指南更是含金量满满，是我们在临床工作中的得力助手。

Cancer Cell：乳腺癌中精氨酸-多胺-TDG通路如何“驯化”巨噬细胞，抑制T细胞抗癌能力

国际顶级期刊《Cancer Cell》（影响因子48.8）近日发表了一项颠覆性研究，首次揭示​

绘真约大咖 | 黄利敏教授：乳腺癌BRCA/HRR基因检测有何意义？胚系与体系突变咋区分？

BRCA 基因胚系突变是家族性乳腺癌等肿瘤核心风险因素。专家解答乳腺癌及良性病变、年轻及晚期乳腺癌患者的基因检测问题，探讨 HRR 通路基因及血浆 ctDNA 检测意义与局限。

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组（统称） · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识（2010版）

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议：乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南：乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南：激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12